Division of Bone and Mineral Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Bone. 2021 Jun;147:115932. doi: 10.1016/j.bone.2021.115932. Epub 2021 Mar 20.
Peripheral neuropathy occurs in two thirds of patients with diabetes mellitus (DM). It can lead to severe pathological changes in the feet, and it increases the risk of fracture more than any other diabetic complication. The objective of this review is to analyze available literature on the effect of peripheral neuropathy on BMD of the foot, spine, or hip. We hypothesize that the presence of diabetic neuropathy leads to lower BMD in adults with diabetes.
Original studies investigating the effects of diabetic neuropathy on bone density were searched for inclusion in this systematic review. Studies were eligible if they met the following criteria: 1) participants included adults with either Type 1 DM or Type 2 DM; 2) Method used for the diagnosis of neuropathy described in the manuscript 3) DXA scan, ultrasound, or CT scan was used to measure proximal femur, spine, or foot bone mineral density were reported, and 4) bone parameters were analyzed based on the presence and absence of neuropathy.
Among the 5 studies that met eligibility criteria, 4 did not find a significant effect of neuropathy on BMD. One study showed a significant negative impact of neuropathy on calcaneal BMD in patients with type 1 diabetes. The meta-analysis did not show a significant effect of peripheral neuropathy on BMDs of proximal femur, spine, and calcaneus in diabetic adults.
Our study shows no evidence that peripheral neuropathy affects bone density or bone turnover in DM. However, this conclusion should be taken with caution since only a very limited number of studies were available for inclusion in the analysis and included both type 1 and type 2 DM patients. Improved measures of peripheral neuropathy and more advanced imaging technologies are needed to better assess the effect of diabetes on bone health.
三分之二的糖尿病(DM)患者会发生周围神经病变。它会导致脚部严重的病理变化,并使骨折风险增加超过任何其他糖尿病并发症。本综述的目的是分析有关周围神经病变对足部、脊柱或臀部骨密度影响的现有文献。我们假设,糖尿病神经病变的存在会导致成年糖尿病患者的骨密度降低。
搜索了关于糖尿病神经病变对骨密度影响的原始研究,以纳入本系统评价。如果研究符合以下标准,则符合入选条件:1)参与者包括 1 型或 2 型糖尿病患者;2)手稿中描述的神经病学诊断方法;3)使用 DXA 扫描、超声或 CT 扫描来测量股骨近端、脊柱或足部骨密度;4)基于神经病的存在和不存在分析骨参数。
在符合入选标准的 5 项研究中,有 4 项研究未发现神经病对骨密度有显著影响。一项研究表明,1 型糖尿病患者的周围神经病对跟骨骨密度有显著的负面影响。荟萃分析未显示周围神经病变对糖尿病成人股骨近端、脊柱和跟骨骨密度有显著影响。
我们的研究没有证据表明周围神经病变会影响 DM 患者的骨密度或骨转换。然而,由于可用于分析的研究数量非常有限,并且包括 1 型和 2 型糖尿病患者,因此应谨慎得出这一结论。需要改进周围神经病变的测量方法和更先进的成像技术,以更好地评估糖尿病对骨骼健康的影响。